Skip to main navigation
MIRUM

Header Menu

  • Who We Are
    • About Mirum
    • Leadership
    • Board of Directors
  • Programs
    • Pipeline
    • Maralixibat
    • Volixibat
    • Publications & Presentations
  • Patients & Families
    • Clinical Trials
    • Expanded Access
    • Progressive Familial Intrahepatic Cholestasis (PFIC)
    • Alagille Syndrome (ALGS)
    • Biliary Atresia (BA)
    • Intrahepatic Cholestasis of Pregnancy (ICP)
    • Primary Sclerosing Cholangitis (PSC)
  • Investors & Media
    • News Releases
    • Events and Presentations
    • Corporate Governance
      • Documents & Charters
      • Board of Directors
      • Management
      • Committee Composition
    • Financials & Filings
      • SEC Filing
    • Stock Information
      • Stock Quote & Chart
      • Historic Price Lookup
      • Investment Calculator
    • Shareholder Services
      • Investor FAQs
      • Email Alerts
      • Contact IR
  • Careers
  • Contact Us
  • Menu

Investor Relations

  • News Releases
  • Events and Presentations
  • Corporate Governance
    • Documents & Charters
    • Board of Directors
    • Management
    • Committee Composition
  • Financials & Filings
    • SEC Filings
    • Analyst Coverage
  • Stock Information
    • Stock Quote & Chart
    • Historic Price Lookup
    • Investment Calculator
  • Shareholder Services
    • Investor FAQs
    • Contact IR
    • Email Alerts

Investor Tools

  • Print

    Print

  • RSS Feeds

    RSS Feeds

  • Email Alerts

    Email Alerts

  • Search

    Search

  • Contact IR

    Contact IR

  • Email Page

    Email Page

SEC Filings

SEC Filings

Filing date Form Description Filing Group Issuer View
Nov 12, 2020 8-K

Report of unscheduled material events or corporate event

Current Reports
Mirum Pharmaceuticals, Inc.
0001564590-20-053195.pdf
0001564590-20-053195.rtf
0001564590-20-053195.xls
View HTML
Nov 12, 2020 10-Q

Quarterly report which provides a continuing view of a company's financial position

Quarterly Filings
Mirum Pharmaceuticals, Inc.
0001564590-20-053201.pdf
0001564590-20-053201.rtf
0001564590-20-053201.xls
EX-101.INS - XBRL INSTANCE DOCUMENT View HTML
Nov 12, 2020 4

Statement of changes in beneficial ownership of securities

3,4,5
Mirum Pharmaceuticals, Inc.
0001209191-20-058024.pdf
0001209191-20-058024.rtf
0001209191-20-058024.xls
View HTML
Nov 12, 2020 4

Statement of changes in beneficial ownership of securities

3,4,5
Mirum Pharmaceuticals, Inc.
0001209191-20-058035.pdf
0001209191-20-058035.rtf
0001209191-20-058035.xls
View HTML
Nov 12, 2020 4

Statement of changes in beneficial ownership of securities

3,4,5
Mirum Pharmaceuticals, Inc.
0001209191-20-058048.pdf
0001209191-20-058048.rtf
0001209191-20-058048.xls
View HTML
Nov 12, 2020 4

Statement of changes in beneficial ownership of securities

3,4,5
Mirum Pharmaceuticals, Inc.
0001209191-20-058044.pdf
0001209191-20-058044.rtf
0001209191-20-058044.xls
View HTML
Nov 12, 2020 4

Statement of changes in beneficial ownership of securities

3,4,5
Mirum Pharmaceuticals, Inc.
0001209191-20-058052.pdf
0001209191-20-058052.rtf
0001209191-20-058052.xls
View HTML
Nov 12, 2020 4

Statement of changes in beneficial ownership of securities

3,4,5
Mirum Pharmaceuticals, Inc.
0001209191-20-058054.pdf
0001209191-20-058054.rtf
0001209191-20-058054.xls
View HTML
Nov 03, 2020 4

Statement of changes in beneficial ownership of securities

3,4,5
Mirum Pharmaceuticals, Inc.
0001209191-20-056690.pdf
0001209191-20-056690.rtf
0001209191-20-056690.xls
View HTML
Aug 12, 2020 EFFECT

EFFECT

Other
Mirum Pharmaceuticals, Inc.
9999999995-20-002122.xls
View HTML

Pagination

  • First page « First
  • Previous page ‹ Previous
  • Page 1
  • Page 2
  • Current page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • …
  • Next page Next ›
  • Last page Last »
Displaying 21 - 30 of 144 results

Data provided by Kaleidoscope.

Header Menu

  • Who We Are
  • About Mirum
  • Leadership
  • Board of Directors
  • Programs
  • Pipeline
  • Maralixibat
  • Volixibat
  • Publications & Presentations
  • Patients & Families
  • Clinical Trials
  • Expanded Access
  • Progressive Familial Intrahepatic Cholestasis (PFIC)
  • Alagille Syndrome (ALGS)
  • Biliary Atresia (BA)
  • Intrahepatic Cholestasis of Pregnancy (ICP)
  • Primary Sclerosing Cholangitis (PSC)
  • Investors & Media
  • News Releases
  • Events and Presentations
  • Corporate Governance
  • Financials & Filings
  • Stock Information
  • Shareholder Services
  • Careers
  • Contact Us
© 2021 – Mirum Pharmaceuticals, Inc.
Scroll to top
  • Facebook
  • Twitter
  • LinkedIn